Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury

恩帕吉菲 韧皮部 药理学 医学 急性肾损伤 肾 TLR4型 化学 糖尿病 2型糖尿病 内科学 内分泌学 炎症 生物化学
作者
Vishwadeep Shelke,Ajinath Kale,Neha Dagar,Tahib Habshi,Anil Bhanudas Gaikwad
出处
期刊:Food & Function [Royal Society of Chemistry]
卷期号:14 (11): 5391-5403 被引量:17
标识
DOI:10.1039/d3fo01379k
摘要

Toll-like receptor-4 (TLR4) and sodium-glucose co-transporter 2 (SGLT2) signaling is involved in the pathogenesis of diabetes-associated kidney diseases. The purpose of this study was to explore the role and effect of phloretin, a TLR4 inhibitor, as an adjuvant therapy to empagliflozin, an SGLT2 inhibitor, in ischemic acute kidney injury (AKI) under diabetic conditions. To achieve this, firstly we induced type 1 diabetes using streptozotocin (55 mg per kg per intraperitoneally (i.p.)) followed by performing bilateral ischemia-reperfusion kidney injury to induce AKI in male Wistar rats. Treatment with phloretin (50 and 100 mg per kg per orally) and empagliflozin (10 mgper kg per orally) alone or in combination was administered to the diabetic rats for 4 days and 1 h before surgery. Moreover, a hypoxia-reperfusion injury was induced using sodium azide in NRK52E cells under a hyperglycemic environment to mimic the in vivo model. The cells were treated with phloretin (50 μM) and empagliflozin (100 nM) for 24 h. For biochemical analysis, plasma and urine samples were used. The kidney tissues were used to perform immunoblotting, histopathology, and immunohistochemistry. Other experiments like immunofluorescence, cell viability assay, and flow cytometry analysis were performed using the in vitro samples. The study outcomes revealed that compared to monotherapy, combination therapy of phloretin and empagliflozin was significantly effective. Phloretin and empagliflozin target the HMGB1/TLR4/MyD88/IK-β/α/NF-κB pathway to reduce inflammation and apoptosis, in addition to their antihyperglycemic effect. Thus, phloretin, a natural dietary supplement, as an adjuvant therapy to empagliflozin can be helpful to reduce empagliflozin-associated side effects, by reducing its clinical dose and increasing its therapeutic efficacy in AKI-diabetes comorbidity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被科研通管家采纳,获得10
刚刚
zilicai的应助被科研通管家采纳,获得20
刚刚
酷波er的应助被科研通管家采纳,获得10
1秒前
华仔的应助被科研通管家采纳,获得10
1秒前
vvv发布了新的文献求助10
1秒前
Nole的应助被科研通管家采纳,获得10
1秒前
1秒前
阿申爱乐的应助被负责的寒烟采纳,获得30
1秒前
1秒前
FashionBoy的应助被Sunny采纳,获得10
1秒前
1秒前
充电宝的应助被科研通管家采纳,获得10
1秒前
赘婿的应助被科研通管家采纳,获得10
1秒前
鳗鱼裙子完成签到,获得积分10
1秒前
顾矜的应助被科研通管家采纳,获得10
1秒前
烟花的应助被科研通管家采纳,获得10
1秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
CodeCraft的应助被科研通管家采纳,获得10
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
CipherSage的应助被科研通管家采纳,获得10
2秒前
1101592875的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
3秒前
vnewgnl的应助被动人的亦云采纳,获得10
3秒前
mbl2006完成签到,获得积分10
3秒前
科研通AI6.4的应助被WHW采纳,获得10
3秒前
糖果发布了新的文献求助10
5秒前
NexusExplorer的应助被海盗船长采纳,获得10
6秒前
dukejoe发布了新的文献求助10
6秒前
7秒前
7秒前
个性小熊猫完成签到,获得积分10
7秒前
lanping666完成签到,获得积分10
9秒前
Melvina完成签到,获得积分10
9秒前
天天快乐的应助被ooa4321采纳,获得10
9秒前
Orange的应助被耶耶业采纳,获得10
9秒前
科研通AI65的应助被赫江涛采纳,获得10
10秒前
敏静发布了新的文献求助10
10秒前
小马甲的应助被克莱不因蓝采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128